Item 7.01 Regulation FD Disclosure.

On January 9, 2023, Relmada Therapeutics, Inc. (the "Company"), issued a press release announcing the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer. Pursuant to Regulation FD, the press release is furnished with this Current Report as Exhibit 99.1.

The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), regardless of any general incorporation language in such filing.




Item 8.01 Other Events.

On January 9, 2023, the Company updated its corporate presentation, a copy of which is filed herewith as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description
99.1*           Press release issued on January 9, 2023
99.2            Corporate Presentation dated January 9, 2023
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)

* This Exhibit attached to this Form 8-K shall not be deemed "filed" for purposes

of Section 18 of the Exchange Act or otherwise subject to liability under that

section, nor shall it be deemed incorporated by reference in any filing under

the Securities Act or the Exchange Act, except as expressly set forth by

specific reference in such filing.






                                       1

© Edgar Online, source Glimpses